Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Regeneron Pharmaceuticals (NASDAQ:REGN) on Friday topped Street forecasts with its Q2 financials, thanks mainly to U.S. sales ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

EYLEA HD prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and EYLEA HDside effects.

Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept, a vascular endothelial growth factor (VEGF) inhibitor.